TCM
KLRS

Tang Capital Management’s Kalaris Therapeutics KLRS Stock Holding History

Tang Capital Management’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-418,241
Closed -$2.42M – 201
2025
Q3 		$2.42M Buy
418,241
+57,382
+16% +$190K 0.09% 119
2025
Q2 		$963K Buy
360,859
+51,638
+17% +$233K 0.05% 155
2025
Q1 		$2.48M Buy
309,221
+285,210
+1,188% +$2.79M 0.14% 103
2024
Q4 		$232K Buy
+24,011
New +$363K 0.02% 179

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Tang Capital Management's KLRS Position: Q4 2025 in Review

Tang Capital Management sold out of Kalaris Therapeutics (KLRS) in Q4 2025, closing a stake of 418,241 shares — an estimated $2.42M sold.

Tang Capital Management first reported a position in KLRS in Q4 2024 and held it in 4 quarters. The position peaked at $2.48M in Q1 2025. 51 funds tracked by Wall St. Rank hold KLRS as of Q4 2025.

  • Tang Capital Management reported no remaining Kalaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Tang Capital Management sold 418,241 Kalaris Therapeutics shares in Q4 2025, an estimated $2.42M.
  • Tang Capital Management first reported a position in Kalaris Therapeutics in Q4 2024 and held it in 4 quarters.
  • Tang Capital Management's Kalaris Therapeutics position peaked at $2.48M in Q1 2025.
  • 51 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2025.

Based on Tang Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.